Cite
Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.
MLA
Green, Michael M. B., et al. “Administration of Plerixafor (a CXCR4 Antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” Biology of Blood & Marrow Transplantation, vol. 21, no. 2, Feb. 2015, pp. S31–32. EBSCOhost, https://doi.org/10.1016/j.bbmt.2014.11.024.
APA
Green, M. M. B., Horwitz, M. E., Kang, Y., Chao, N. J., Long, G. D., Rizzieri, D., Gasparetto, C., Sung, A. D., Sarantopoulos, S., Li, Z., Corbet, K., Riggan-Stuelke, E., Sullivan, K., Wilson, B., Chhabra, S., Costa, L. V., Mims, A., & Stuart, R. (2015). Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial. Biology of Blood & Marrow Transplantation, 21(2), S31–S32. https://doi.org/10.1016/j.bbmt.2014.11.024
Chicago
Green, Michael M.B., Mitchell E. Horwitz, Yubin Kang, Nelson J. Chao, Gwynn D. Long, David Rizzieri, Cristina Gasparetto, et al. 2015. “Administration of Plerixafor (a CXCR4 Antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” Biology of Blood & Marrow Transplantation 21 (2): S31–32. doi:10.1016/j.bbmt.2014.11.024.